Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P14555

UPID:
PA2GA_HUMAN

ALTERNATIVE NAMES:
GIIC sPLA2; Group IIA phospholipase A2; Non-pancreatic secretory phospholipase A2; Phosphatidylcholine 2-acylhydrolase 2A

ALTERNATIVE UPACC:
P14555; A8K5I7; Q6DN24; Q6IBD9; Q9UCD2

BACKGROUND:
The protein Phospholipase A2, membrane associated, also referred to as Group IIA phospholipase A2, is integral to antimicrobial defense and the inflammatory response. It hydrolyzes phospholipids, contributing to the generation of free fatty acids and lipid mediators crucial for pathogen clearance and immune activation. Additionally, it plays a regulatory role in intestinal stem cell differentiation and tissue regeneration.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Phospholipase A2, membrane associated, offers promising avenues for therapeutic intervention. Its critical roles in host defense, inflammation, and tissue healing underscore its potential as a target for drug discovery in managing bacterial infections and promoting tissue repair.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.